ArticleGene therapy2004
Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 57 citations in OpenAlex.
- Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral interventions.Applied microbiology and biotechnology · 2021Article
- Multifunctional Delivery Systems for Peptide Nucleic Acids.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Caspase-Activated Oligonucleotide Probe.Bioconjugate chemistry · 2020Article
- Comparing Agent-Based Delivery of DNA and PNA Forced Intercalation (FIT) Probes for Multicolor mRNA Imaging.Chembiochem : a European journal of chemical biology · 2019Article
- Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.Journal of controlled release : official journal of the Controlled Release Society · 2012Review
- Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
- Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex.Nucleic acids research · 2011Article
- Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.British journal of pharmacology · 2009Review
- Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA.Bioconjugate chemistry · 2008Article
- Recent developments in peptide-based nucleic acid delivery.International journal of molecular sciences · 2008Article
- Membrane transducing activity of recombinant Hoxc8 protein and its possible application as a gene delivery vector.Experimental & molecular medicine · 2008Article
- A non-covalent peptide-based carrier for in vivo delivery of DNA mimics.Nucleic acids research · 2007Article
- Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo.Nucleic acids research · 2006Article
- Epigenetic manipulation of gene expression: a toolkit for cell biologists.The Journal of cell biology · 2005Review
- Nuclear entry of nonviral vectors.Gene therapy · 2005Review
- Intracellular trafficking of nucleic acids.Expert opinion on drug delivery · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The design of potent systems for the delivery of charged and noncharged molecules that target genes of interest remains a challenge. We describe a novel technology that combines a new generation of peptide nucleic acids (PNAs), or HypNA-pPNAs, with a new noncovalent peptide-based delivery system, Pep-2, which promotes efficient delivery of PNAs into several cell lines. We have validated the potential of this technology by showing that Pep2-mediated delivery of an antisense HypNA-pPNA chimera directed specifically against cyclin B1 induces rapid and robust downregulation of its protein levels and efficiently blocks cell cycle progression of several cell lines, as well as proliferation of cells derived from a breast cancer. Pep-2-based delivery system was shown to be 100-fold more efficient in delivering HypNA-pPNAs than classical cationic lipid-based methods. Whereas Pep-2 is essential for improving the bioavailability of PNAs and HypNA-pPNAs, the latter contribute significantly to the efficiency and specificity of the biological response. We have found that Pep-2/HypNA-pPNA strategy promotes potent antisense effects, which are approximately 25-fold greater than with classical antisense oligonucleotide directed specifically against the same cyclin B1 target. Taken together, these data demonstrate that peptide-mediated delivery of HypNA-pPNAs constitutes a very promising technology for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.